<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2019-6-75-79</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-2336</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МНЕНИЕ ПО ПРОБЛЕМЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OPINION ON A PROBLEM</subject></subj-group></article-categories><title-group><article-title>Статины и риск развития катаракты</article-title><trans-title-group xml:lang="en"><trans-title>Statins and the risk of cataract</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2960-7044</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бутина</surname><given-names>Е. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Butina</surname><given-names>E. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бутина Екатерина К. — кандидат медицинских наук, старший научный сотрудник лаборатории медикаментозной профилактики в первичном звене здравоохранения отдела первичной профилактики хронических неинфекционных заболеваний в системе здравоохранения.</p><p>Москва.</p><p>Тел.: +7 (910) 400-19-84</p></bio><bio xml:lang="en"/><email xlink:type="simple">ebutina@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0836-7539</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бочкарева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bochkareva</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бочкарева Елена В. — доктор медицинских наук, руководитель лаборатории.</p><p>Москва.</p></bio><bio xml:lang="en"/><email xlink:type="simple">EBochkareva@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5122-4723</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ким</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kim</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ким Ирина В. — кандидат медицинских наук, научный сотрудник лаборатории.</p><p>Москва.</p></bio><bio xml:lang="en"/><email xlink:type="simple">IKim@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр профилактической медицины Минздрава России</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for Preventive</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>15</day><month>10</month><year>2019</year></pub-date><volume>18</volume><issue>6</issue><fpage>75</fpage><lpage>79</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бутина Е.К., Бочкарева Е.В., Ким И.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Бутина Е.К., Бочкарева Е.В., Ким И.В.</copyright-holder><copyright-holder xml:lang="en">Butina E.K., Bochkareva E.V., Kim I.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/2336">https://cardiovascular.elpub.ru/jour/article/view/2336</self-uri><abstract><p>Статины являются одним из наиболее часто назначаемых классов препаратов для профилактики сердечно-сосудистых заболеваний и лечения гиперлипидемии. В литературе встречаются сведения об ассоциации риска развития катаракты на фоне приема статинов. В то же время имеются работы, где описан протективный эффект статинов в отношении катаракты. В связи с тем, что с возрастом риск развития катаракты увеличивается, так же, как и вероятность назначения статинов, проблема побочных эффектов при их применении имеет особую значимость. Несмотря на противоречивые результаты, многие авторы сходятся во мнении, что в настоящий момент нет убедительных причин для отказа от назначения статинов, поскольку преимущества в снижении риска сердечно-сосудистых заболеваний значительно перевешивают риск развития катаракты и возможную потребность в ее хирургическом лечении. В работе представлены 2 систематических обзора и 3 мета-анализа, посвященных изучению ассоциации приема статинов и риска развития катаракты или хирургического лечения этого заболевания, а также исследования на эту тему, выполненные за последние 5 лет.</p></abstract><trans-abstract xml:lang="en"><p>Statins are one of the most commonly prescribed classes of drugs for the cardiovascular disease prevention and the treatment of hyperlipidemia. In the literature there is information about the association of statin taking and higher cataract risk. At the same time, there are studies that describe the protective effect of statins on cataracts. Due to the fact that with age the risk cataract increases, as does the likelihood of prescribing statins, the problem of side effects with its use is of particular importance. Despite the conflicting results, many authors agree that there is no convincing reason for statin refuse, since the advantages in cardiovascular risk reducing far outweigh the cataract risk and the possible need for its surgical treatment. The study presents 2 systematic reviews and 3 meta-analyzes about association of statin intake and cataract risk or its surgical treatment, as well as studies carried out over the past 5 years.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>статины</kwd><kwd>катаракта</kwd><kwd>побочный эффект</kwd><kwd>защитный (протективный) эффект</kwd></kwd-group><kwd-group xml:lang="en"><kwd>statins</kwd><kwd>cataract</kwd><kwd>side effect</kwd><kwd>protective effect</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Официальная инструкция к препарату Липримар https://medi.ru/instrukciya/liprimar_10380/ дата последнего обновления 01.05.2011, дата последнего доступа 11.07.2019.</mixed-citation><mixed-citation xml:lang="en">Официальная инструкция к препарату Липримар https://medi.ru/instrukciya/liprimar_10380/ дата последнего обновления 01.05.2011, дата последнего доступа 11.07.2019.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Официальная инструкция к препарату Крестор https://medi.ru/instrukciya/krestor_4761/ дата последнего обновления 07.09.2016, дата последнего доступа 11.07.2019.</mixed-citation><mixed-citation xml:lang="en">Официальная инструкция к препарату Крестор https://medi.ru/instrukciya/krestor_4761/ дата последнего обновления 07.09.2016, дата последнего доступа 11.07.2019.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Официальная инструкция к препарату Зокор https://medi.ru/instrukciya/zokor-forte_11282/ дата последнего обновления 0104.2016, дата последнего доступа 11072019.</mixed-citation><mixed-citation xml:lang="en">Официальная инструкция к препарату Зокор https://medi.ru/instrukciya/zokor-forte_11282/ дата последнего обновления 0104.2016, дата последнего доступа 11072019.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hartman HA, Myers LA, Evans M, et al. The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and rhesus monkeys. Fundam Appl Toxicol. 1996;29:48-62.</mixed-citation><mixed-citation xml:lang="en">Hartman HA, Myers LA, Evans M, et al. The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and rhesus monkeys. Fundam Appl Toxicol. 1996;29:48-62.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Wise SJ, Nathoo NA, Etminan M, et al. Statin use and risk for cataract: a nested case-control study of 2 populations in Canada and the United States. Can J Cardiol. 2014;30:1613-9. doi:10.1016/j.cjca.2014.08.020.</mixed-citation><mixed-citation xml:lang="en">Wise SJ, Nathoo NA, Etminan M, et al. Statin use and risk for cataract: a nested case-control study of 2 populations in Canada and the United States. Can J Cardiol. 2014;30:1613-9. doi:10.1016/j.cjca.2014.08.020.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Alves C, Mendes D, Marques FB. Statins and risk of cataracts: a systematic review and meta-analysis of observational studies. Cardiovasc Ther. 2018;36(6):e12480. doi:10.1111/1755-5922.12480.</mixed-citation><mixed-citation xml:lang="en">Alves C, Mendes D, Marques FB. Statins and risk of cataracts: a systematic review and meta-analysis of observational studies. Cardiovasc Ther. 2018;36(6):e12480. doi:10.1111/1755-5922.12480.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Erie JC, Pueringer MR, Brue SM, et al. Statin Use and Incident Cataract Surgery: A Case-Control Study. Ophthalmic Epidemiol. 2016;23(1):40-5. doi:10.3109/09286586.20151077258.</mixed-citation><mixed-citation xml:lang="en">Erie JC, Pueringer MR, Brue SM, et al. Statin Use and Incident Cataract Surgery: A Case-Control Study. Ophthalmic Epidemiol. 2016;23(1):40-5. doi:10.3109/09286586.20151077258.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ooi KG-J, Khoo P, Vaclavik V, Watson SL. Statins in ophthalmology. Survey of ophthalmology. 2019;64:401-32. doi:10.1016/j.survophthal.2019.01.013.</mixed-citation><mixed-citation xml:lang="en">Ooi KG-J, Khoo P, Vaclavik V, Watson SL. Statins in ophthalmology. Survey of ophthalmology. 2019;64:401-32. doi:10.1016/j.survophthal.2019.01.013.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lai CL, Shau WY, Chang CH, et al. Statin use and cataract surgery: a nationwide retrospective cohort study in elderly ethnic Chinese patients. Drug Saf. 2013;36(10):1017-24. doi:10.1007/s40264-013-0076-0.</mixed-citation><mixed-citation xml:lang="en">Lai CL, Shau WY, Chang CH, et al. Statin use and cataract surgery: a nationwide retrospective cohort study in elderly ethnic Chinese patients. Drug Saf. 2013;36(10):1017-24. doi:10.1007/s40264-013-0076-0.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cenedella RJ. Cholesterol and cataracts. Surv Ophthalmol. 1996;40(4):320-37.</mixed-citation><mixed-citation xml:lang="en">Cenedella RJ. Cholesterol and cataracts. Surv Ophthalmol. 1996;40(4):320-37.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Leuschen J, Mortensen EM, Frei CR, et al. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 2013;131(11):1427-34. doi:10.1001/jamaophthalmol.2013.4575.</mixed-citation><mixed-citation xml:lang="en">Leuschen J, Mortensen EM, Frei CR, et al. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 2013;131(11):1427-34. doi:10.1001/jamaophthalmol.2013.4575.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373-418. doi:10.2165/0129784-200808060-00004.</mixed-citation><mixed-citation xml:lang="en">Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373-418. doi:10.2165/0129784-200808060-00004.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Broniarek I, Jarmuszkiewicz W. Statins and mitochondria. Postepy Biochem. 2016;62(2):77-84.</mixed-citation><mixed-citation xml:lang="en">Broniarek I, Jarmuszkiewicz W. Statins and mitochondria. Postepy Biochem. 2016;62(2):77-84.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Klein BE, Klein R, Lee KE, Danforth LG. Drug use and five-year incidence of age-related cataracts: The Beaver Dam Eye Study. Ophthalmology. 2001;108(9):1670-4. doi:101016/s0161-6420(01)00656-x.</mixed-citation><mixed-citation xml:lang="en">Klein BE, Klein R, Lee KE, Danforth LG. Drug use and five-year incidence of age-related cataracts: The Beaver Dam Eye Study. Ophthalmology. 2001;108(9):1670-4. doi:101016/s0161-6420(01)00656-x.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Stoll LL, McCormick ML, Denning GM, Weintraub NL. Antioxidant effects of statins. Drugs Today (Barc). 2004;40(12):975-90.</mixed-citation><mixed-citation xml:lang="en">Stoll LL, McCormick ML, Denning GM, Weintraub NL. Antioxidant effects of statins. Drugs Today (Barc). 2004;40(12):975-90.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: a population-based cohort using the QResearch database. BMJ. 2010;340:c2197 doi:10.1136/bmj.c2197.</mixed-citation><mixed-citation xml:lang="en">Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: a population-based cohort using the QResearch database. BMJ. 2010;340:c2197 doi:10.1136/bmj.c2197.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Fong DS, Poon KY. Recent statin use and cataract surgery. Am J Ophthalmol. 2012;153:222-8. doi:10.1016/j.ajo.2011.08.001.</mixed-citation><mixed-citation xml:lang="en">Fong DS, Poon KY. Recent statin use and cataract surgery. Am J Ophthalmol. 2012;153:222-8. doi:10.1016/j.ajo.2011.08.001.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet. 2002;360:7-22. doi:10.1016/S0140-6736(02)09327-3.</mixed-citation><mixed-citation xml:lang="en">Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet. 2002;360:7-22. doi:10.1016/S0140-6736(02)09327-3.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Klein BE, Klein R, Lee KE, Grady LM. Statin use and incident nuclear cataract. JAMA. 2006;295:2752-8. doi:10.1001/jama.295.23.2752.</mixed-citation><mixed-citation xml:lang="en">Klein BE, Klein R, Lee KE, Grady LM. Statin use and incident nuclear cataract. JAMA. 2006;295:2752-8. doi:10.1001/jama.295.23.2752.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tan JS, Mitchell P, Rochtchina E, Wang JJ. Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. Am J Ophthalmol. 2007;143:687-9. doi:10.1016/j.ajo.2006.11.027.</mixed-citation><mixed-citation xml:lang="en">Tan JS, Mitchell P, Rochtchina E, Wang JJ. Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. Am J Ophthalmol. 2007;143:687-9. doi:10.1016/j.ajo.2006.11.027.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kostis JB, Dobrzynski JM. Prevention of Cataracts by Statins: A Meta-Analysis. J Cardiovasc Pharmacol Ther. 2013;4:1-10. doi:101177/1074248413511690.</mixed-citation><mixed-citation xml:lang="en">Kostis JB, Dobrzynski JM. Prevention of Cataracts by Statins: A Meta-Analysis. J Cardiovasc Pharmacol Ther. 2013;4:1-10. doi:101177/1074248413511690.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Yu Sh, Chu Y, Li G, et al. Statin Use and the Risk of Cataracts: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017;6: pii: e004180. doi:10.1161/JAHA.116.004180.</mixed-citation><mixed-citation xml:lang="en">Yu Sh, Chu Y, Li G, et al. Statin Use and the Risk of Cataracts: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017;6: pii: e004180. doi:10.1161/JAHA.116.004180.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Bosch J, Dagenais G, et al. for the HOPE-3 Investigators. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2021-31. doi: 101056/NEJMoa1600176.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Bosch J, Dagenais G, et al. for the HOPE-3 Investigators. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2021-31. doi: 101056/NEJMoa1600176.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bang CN, Greve AM, La Cour M, et al. Effect of randomized lipid lowering with simvastatin and ezetimibe on cataract development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study). Am J Cardiol. 2015;116:1840-4. doi:101016/j.amjcard.2015.09.026.</mixed-citation><mixed-citation xml:lang="en">Bang CN, Greve AM, La Cour M, et al. Effect of randomized lipid lowering with simvastatin and ezetimibe on cataract development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study). Am J Cardiol. 2015;116:1840-4. doi:101016/j.amjcard.2015.09.026.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Holou SN, Tucker WR, Agron E, et al. The Association of Statin Use with Cataract Progression and Cataract Surgery The Age-Related Eye Disease Study 2 Report Number 8 Ophthalmology. 2016;123(4):916-7. doi:10.1016/j.ophtha.2015.10.040.</mixed-citation><mixed-citation xml:lang="en">Al-Holou SN, Tucker WR, Agron E, et al. The Association of Statin Use with Cataract Progression and Cataract Surgery The Age-Related Eye Disease Study 2 Report Number 8 Ophthalmology. 2016;123(4):916-7. doi:10.1016/j.ophtha.2015.10.040.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532-61. doi:101016/S0140-6736(16)31357-5.</mixed-citation><mixed-citation xml:lang="en">Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532-61. doi:101016/S0140-6736(16)31357-5.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Mancini GBJ, Baker S, Bergeron J, et al. Diagnosis, Prevention and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016; 32(7): S35-65. doi:101016/j.cjca.2016.01.003.</mixed-citation><mixed-citation xml:lang="en">Mancini GBJ, Baker S, Bergeron J, et al. Diagnosis, Prevention and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016; 32(7): S35-65. doi:101016/j.cjca.2016.01.003.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
